RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Meccanismi molecolari di carcinogenesi: validazione di nuovi bersagli per la diagnosi e la terapia
• 2 - Marcatori molecolari nel carcinoma del cavo orale e loro impiego nella diagnosi precoce, nella prognosi e nella risposta ai farmaci antiblastici.
• 3 - Studio delle alterazioni biomolecolari e dei profili di espressione genica nel carcinoma colorettale e pancreatico: identificazione di possibili elementi prognostici e bersagli terapeutici nel sistema degli eicosanoidi e dei cannabinoidi.
• 4 - RUOLO DELLE CELLULE DENDRITICHE, DELLE CITOCHINE E DEGLI ORMONI STEROIDEI SESSUALI NELLA STORIA NATURALE DELLE MALATTIE EPATICHE CRONICHE
• 5 - Studio dei meccanismi molecolari alla base dell’anomala proliferazione e funzione paratiroidea, e identificazione ed uso clinico di marcatori molecolari di carcinoma paratiroideo sporadico e familiare. Nuove acquisizione sulla prevalenza delle manifestazioni scheletriche, neuropsichiche e metaboliche dell’iperparatiroidismo primario, loro relazione con i polimorfismi del recettore del calcio ed effetti della paratiroidectomia.
• 6 - Meccanismi di controllo dell’eritropoiesi e policitemie congenite e familiari: ruolo delle vie di risposta alla pressione di ossigeno
• 7 - Caratterizzazione molecolare dell'eritropoiesi:analisi post-genomica e funzionale del profilo di espressione proteica
• 8 - Basi strutturali dei meccanismi di azione di fattori oncogenici e oncosoppressori nei tumori del sistema nervoso:progettazione di nuove entità molecolari di interesse terapeutico.
• 9 - Medulloblastoma: studio delle vie molecolari di sviluppo e progressione tumorale allo scopo di identificare approcci terapeutici innovativi
• 10 - Progressione dei carcinomi della ghiandola mammaria e della prostata: nuovi meccanismi ormonali e approcci terapeutici.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • FARMACOLOGIA
• Area scientifico disciplinare: Scienze mediche
  • ONCOLOGIA MEDICA
  • MEDICINA INTERNA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Sicilia

Bibliografia

1-Frommel TO et al. Immunohistochemical evaluation of Bcl-2 gene family expression in liver of hepatitis C and cirrhotic patients: a novel mechanism to explain the high incidence of hepatocarcinoma in cirrhotics. Am J Gastroenterol 94: 178-82, 1999.
2-T. Ito et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31:1080-1085, 2000.
3-M. Ikeguchi et al. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer 95:1938-194, 2002.
4-K. Shiraki et al. Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int. J. Mol. Med. 12: 705-708, 2003.
5-M. Notarbartolo et al. Expression of IAPs and of their alternative splice variants in hepatocellular carcinoma tissues and cells. Ann N Y Acad Sci. 1028: 289-293, 2004.
6-Mahotka C et al. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59: 6097-102, 1999.
7-Notarbartolo M et al. NAIP-deltaEx10-11: a novel splice variant of the apoptosis inhibitor NAIP differently expressed in drug-sensitive and multidrug-resistant HL60 leukemia cells. Leuk Res. 26: 857-62, 2002.
8-Q. L. Deveraux , J.C. Reed. IAP family proteins-suppressors of apoptosis. Genes & Dev. 13: 239-252, 1999.
9-Notarbartolo M et al. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (Inhibitory of Apoptosis Proteins). Cancer Lett 180: 91-101, 2002.
10-Tas F et al. Serum bcl-2 and survivin levels in melanoma. Melanoma Res 14: 543-6, 2004.
11-Fields AC et al. Mod Pathol. 17:1 378-385, 2004.
12-Kannangai R et al. Int J Gastrointest Cancer 35: 53-60, 2005.
13-Takashima H et al.In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int. 25: 77-84, 2005.
14-N. Mitsiades et al. Blood 99: 4079-86, 2002.
15-P. Liu et al. Activation of NF-kappaB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J. Hepatol. 37: 63-7, 2002.
16-M. Notarbartolo et al. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. In press on Cancer Letters.
17-Tran J et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 99: 4349-54, 2002.
18-M. Fornaro et al. Fibrinonectin protects prostate cancer cells from tumor necrosis factor alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 278: 40402-11, 2003.
19-H.C. Dan et al. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 23: 706-15, 2004.
20-Wall NR et al. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 63: 230-5, 2003.
21-Suzuki A et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19: 1346-53, 2000.
22-Kitada S et al. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96: 393-7, 2000.
23-Castagnetta L et al. Local estrogen formation by non-tumoral, cirrhotic and malignant liver tissues and cells. Cancer Res. 63: 5041-5045, 2003.
24-Frasor J et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144: 4562-74, 2003.
25-Takeda H et al.Cancer Res. 63(16): 4872-4877, 2003.
26-Kitamura T. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis 23(9):1463-1466, 2002.
27-Bae SH et al. Expression of cyclooxigenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cells by a cyclooxigenase-2 inhibitor, NS-398. Clin. Cancer Res. 7: 1410-1418, 2001.
28-Foderà D et al. Induction of Apoptosis and Inhibition of Cell Growth in Human Hepatocellular Carcinoma Cells by COX-2 Inhibitors. Ann N Y Acad Sci 1028:440-449, 2004.
29-Hu KQ et al. Int. J. Oncol. 22-(4):757-763, 2003.
30-Majima M et al. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci. 24(10):524-9, 2003.
31-Fujino H et al. J Biol Chem 277: 2614-2619, 2002.
32-Shao J et al. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63: 5218-5223, 2003.
33-Shoji Y et al.Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 53: 1151-8, 2004.
34-Davies G et al. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer. chemoprevention. Ann Oncol. 13: 669-78, 2002.
35-Krysan K et al. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 64(18):6359-62, 2004.
36-Fantappie O et al. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 35(4): 843-852, 2002.
37-Subbaramaiah K et al. J Biol Chem 275(20):14838-45, 2000.
38-Tsuji M, Dubois RN. Cell 83: 493-501, 1995.
39-Oesterreich S et al. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. Cancer Res. 63:5203-8, 2003.
40-Carruba G et al. Sex steroids up-regulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells. Biochem. Biophys. Res. Commun. 212: 624-631, 1995.
41-Tsujii M et al. Cell 93:705-716, 1998.
42-Buendia MA. Semin Cancer Biol. 10: 185-200, 2000.
43-Levrero M et al. Structure, function and regulation of p63 and p73. Cell Death and Differentiation 7, 565-574, 1999.
44-Levrero M et al. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci. 113, 1661-70, 2000.
45-De Laurenzi, V et al. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med. ; 188: 1763-1768; 1998.
46-De Laurenzi V et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and theta. Cell Death Differ. 6: 389-390, 1999.
47-Flores ER et al. (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature, 416:560-564.
48-Bergamaschi D et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003 Apr;3(4):387-402.
49-Pediconi N et al. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol. 2003 Jun;5(6):552-8.
50-Vossio, S et al. DN-p73 is activated after DNA damage in a p53 dependent manner to regulate p53-induced cell cycle arrest. Oncogene 2002, 21, 3796-3803.
51-Papoutsaki M et al.(2004) The p73 gene is an anti-tumoral target of the RARbeta/gamma-selective retinoid tazarotene J Invest Dermatol. 113, 1162-1168.
52-Damalas A et al. Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J; 18 (11): 3054-3063; 1999.
53-Gong JG et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806-809;1999.
54-Costanzo A et al. DNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes. Mol Cell. 9:175-86, 2002.
55-Lunghi P et al. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the P73.P53AIP1 apoptotic pathway in leukemia cells. Blood 104, 1-6, 2004.

Parole Chiave

CARCINOMA EPATOCELLULARE; FARMACORESISTENZA; APOPTOSI; INHIBITORY OF APOPTOSIS PROTEINS; CICLOSSIGENASI; AROMATASI; P53, P63, P73; FATTORI DI TRASCRIZIONE; FATTORI DI CRESCITA